Lupin Ltd – From TB Pills to Wall Street Thrills: ₹88,000 Cr Pharma’s FDA Love-Hate Story
1. At a Glance
Lupin isn’t just a pharma company; it’s the Bollywood superstar of generics—great opening weekends (US launches), some flop sequels (FDA warnings), and surprise comebacks (biosimilars). With ₹23,376 Cr revenue in FY25, ₹3,699 Cr PAT, and a global footprint in 100+ markets, Lupin is India’s #6 pharma player by sales and #3 generic firm in the US by prescriptions. The share at ₹1,944 trades at 24x P/E—cheaper than Cipla, costlier than Dr. Reddy’s—basically mid-budget entertainer.
2. Introduction
If Sun Pharma is Big B, Lupin is Shah Rukh Khan—sometimes ruling the US box office, sometimes stuck in a “Dilwale”-like compliance fiasco. Born in Mumbai, Lupin has grown into a transnational force with 15 plants, 7 research centers, and more FDA inspections than most desi restaurants in New Jersey.
But the plot twist? The US business—once the star of the show—is now facing tough competition, while Indian brands and biosimilars are slowly stepping into the limelight. Add in R&D spends of 8–9% of turnover and flashy US launches (Albuterol, Risperidone LAI, Prucalopride), and Lupin keeps investors glued, popcorn in hand.
Question: Can Lupin’s biosimilar & complex generics dream make it a global Oscar winner, or will FDA forms 483 keep it typecast as a “compliance struggler”?
3. Business Model – WTF Do They Even Do?
Generic Formulations (60%+ revenue): Cardiovascular, diabetology, respiratory, CNS, GI. Basically, if your family WhatsApp group has BP, sugar, asthma, or anxiety updates, Lupin has a pill for it.
APIs (5% revenue): Cephalosporins & anti-TB APIs where Lupin is global leader.
Branded Drugs (India & EM): MindNext (CNS), Inspire (Diabetes), Maxter Neo (Anti-infectives). India contributes ~34% of revenue.
US Business (38% of revenue): 457 ANDAs filed, 297 approved. Leader in Albuterol (23% market share). Pipeline includes 40+ injectables & 20+ inhalation products.
Biosimilars & Complex Generics (Future bet): Ranibizumab biosimilar with Sandoz, Liraglutide, Glucagon approvals, Certolizumab out-licensed. Target 20 launches by 2028.
So yes, Lupin sells everything from TB drugs in Africa to biosimilars in France, like a Big Bazaar of pharma—except Big Bazaar shut down, Lupin hasn’t. Yet.
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹Cr)
6,268
5,600
5,667
11.9%
10.6%
EBITDA (₹Cr)
1,727
1,241
1,321
39.1%
30.7%
PAT (₹Cr)
1,219
806
782
51.2%
55.8%
EPS (₹)
26.7
17.6
16.9
51.7%
58.0%
Commentary: PAT doubled faster than onion prices in monsoon. EBITDA margins at 28%—clearly Lupin has found its “gym body” phase after years of flab.
